期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 41, 期 5, 页码 906-913出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-021-00997-6
关键词
Infectious disease; Serology; Coronavirus
类别
资金
- Intramural Research Program of the NIH
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
Researchers evaluated the presence of serum antibodies of people worldwide experiencing the pandemic using recombinant proteins from the viral genome. They found potential cross-reactivity of SARS-CoV-2 antibodies with other coronaviruses, with the strongest recognition between SARS-CoV-2 and SARS/MERS-CoV antibodies. Further analysis of cross-reactivity could lead to intelligently designed pan-coronavirus therapeutics or vaccines.
In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据